文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV感染者肌注长效卡博特韦与利匹韦林的血浆及胞内暴露研究

The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该单中心前瞻性观察队列纳入177例换用每8周肌注CAB/RPV(无口服导入)的HIV感染者,随访12个月。CAB与RPV血浆谷浓度个体内变异中等、个体间变异高,RPV胞内蓄积约为血浆5倍,CAB胞内暴露约为血浆15%。第3个月出现血浆与胞内浓度一过性下降但未影响病毒学抑制,病毒学失败2例伴NNRTI和INSTI耐药突变。

要点

  • RPV胞内蓄积约为血浆5倍,CAB胞内暴露约为血浆15%。
  • 第3个月浓度一过性下降,未影响病毒学抑制。
  • 病毒学失败2例出现NNRTI和INSTI主要及辅助耐药突变。

核心结论

  • 肌注LA CAB/RPV血浆暴露与临床试验一致,尽管存在药代动力学变异仍维持病毒学抑制。
  • 胞内蓄积尤其是RPV可能有助于持续病毒学控制。

研究设计与样本

  • 单中心前瞻性观察队列研究,纳入177例换用每8周肌注CAB/RPV(无口服导入)的HIV感染者。
  • 基线和12个月内每次随访检测血浆及外周血单核细胞胞内药物浓度,分析病毒学抑制、免疫参数与PK数据相关性。

主要发现

  • 基线93.6%参与者病毒载量检测不到(<20 copies/mL)。
  • CAB和RPV血浆谷浓度个体内变异中等、个体间变异高。
  • RPV胞内蓄积约为血浆5倍,CAB胞内暴露约为血浆15%。
  • 第3个月血浆和胞内浓度一过性下降,未影响病毒学抑制。
  • 病毒学blips发生率为15.3%,与药物浓度无显著关联;报告2例病毒学失败伴NNRTI和INSTI主要及辅助耐药突变。

临床怎么用

  • 支持LA CAB/RPV作为真实世界临床中稳健的ART选择。
  • 治疗中需关注个体间药代动力学高变异及第3个月浓度一过性下降。
  • 病毒学失败时需警惕NNRTI和INSTI耐药突变。

局限性

  • 单中心前瞻性观察性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Long-acting (LA) intramuscular cabotegravir (CAB) and rilpivirine (RPV) represent a novel antiretroviral therapy (ART) option for people with HIV (PWH), offering improved adherence and patient convenience. The aim was to evaluate plasma and intracellular (IC) exposure of CAB and RPV in PWH switching from oral ART to LA injectable regimens and to assess correlations with virological outcomes and clinical parameters. METHODS: This is a monocentric prospective observational cohort study. We enrolled 177 PWH who switched to CAB/RPV intramuscular injections every 8 weeks without oral lead-in. Plasma and IC drug concentrations in peripheral blood mononuclear cells were measured at baseline and at every follow-up visit over 12 months. Virological suppression, immunological parameters and correlations with PK data were analysed. RESULTS: At baseline, 93.6% of participants had undetectable viral load (<20 copies/mL). CAB and RPV plasma trough concentrations showed moderate intra-individual and high inter-individual variability, with RPV IC accumulation ∼ 5-fold higher than plasma, and CAB IC exposure about 15% of plasma levels. A transient decrease in plasma and IC concentrations was observed at month 3, without impact on virological suppression. Virological blips occurred in 15.3% of participants, with no significant association to drug concentrations. Two virological failures are reported with onset of NNRTI and INSTI major and accessory resistance mutation. CONCLUSIONS: LA CAB and RPV achieve plasma exposures consistent with clinical trials, maintaining virological suppression despite pharmacokinetic variability. Intracellular accumulation, especially of RPV, may contribute to sustained virological control. These findings support the use of LA CAB/RPV as a robust ART option in real-world clinical practice.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ferrara M, Maccario V, Barrera F, et al. The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV. J Antimicrob Chemother. 2026. PMID: 41937337. doi:10.1093/jac/dkag113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。